NewsTrending topic
FDA Expands Anktiva to Papillary-Only Bladder Cancer That Stopped Responding to BCG
On 14 October 2026 the FDA widened the approved use of Anktiva, given with BCG, to adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and did not respond to BCG.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What changed on 14 October 2026
The FDA widened the approved use of Anktiva. It is given together with BCG. The new group is adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG.
The FDA says Anktiva is the first approved treatment for this group. Anktiva was already approved for a different form of the same disease, called carcinoma in situ. We explain the drug itself in our earlier page on Anktiva and IL-15 immunotherapy.
Words that matter here
- Non-muscle invasive bladder cancer is bladder cancer that has not grown into the muscle layer of the bladder wall.
- Carcinoma in situ forms flat patches along the lining. It is always high-grade.
- Papillary tumors grow out from the lining as small, finger-like growths. They can be low-grade or high-grade.
- High-grade cancers are more likely to grow and spread than low-grade cancers.
- BCG is a treatment placed in the bladder that wakes up the immune system there. Sometimes the cancer stays or comes back after BCG. Doctors call that BCG-unresponsive.
Our guide to bladder cancer types has more.
Why the FDA did it this way
The FDA did not run a new trial for this group. It used the results from the earlier approval and compared the two kinds of cancer. The agency says they often occur together, can be hard to tell apart under a microscope, and both carry a high risk of coming back or getting worse when BCG stops working.
The FDA calls this a new approach. It says it is working to finish draft guidance so that drug makers can use the same idea.
What the evidence is
The results come from the trial behind the earlier approval, NCT03022825. It tested Anktiva in 77 adults, and some of them also had papillary tumors.
- 62% had a complete response. That means no high-grade cancer was found at follow-up.
- Of those, 58% kept the response for at least 12 months.
- 40% kept it for at least 24 months.
These numbers describe the trial group. This approval rests on those results plus laboratory and clinical evidence about how alike the two cancers are. It did not rest on a new trial in papillary-only disease.
How treatment works
Anktiva is given with BCG through a catheter into the bladder. It is given once a week for six weeks. More treatment depends on how the cancer responds. It can go on for up to 37 months.
The FDA says treatment should stop if the cancer persists after a second six-week course, comes back or gets worse, or the side effects become unacceptable.
Side effects
The FDA lists these as the most common:
- Painful or frequent urination
- A sudden need to urinate
- Blood in the urine
- Urinary tract infections
- Muscle or joint pain
- Chills and fever
- Higher blood levels of creatinine and potassium
The prescribing information also warns that putting off surgery to remove all or part of the bladder can let the cancer spread to other parts of the body. That can be fatal. This is part of why the choice to try treatment first, or to have surgery, is one to make with your urologist.
Ask your team before treatment starts
- Which symptoms need a same-day call to the clinic, and what is the after-hours number?
- How will we know if the cancer is responding, and when will you check?
- What would make us stop, and what would the next step be?
- If I wait on surgery, what is the risk, and what are the signs it is time?
Call 911 or go to the nearest emergency room if you cannot pass urine, have severe pain, or feel faint or confused.
What this approval does not mean
- It does not cover bladder cancer that has grown into the bladder muscle.
- It does not mean Anktiva works for everyone. In the trial, 62% had a complete response.
- It does not replace surgery for people whose doctors advise it.
- It does not tell you what is right for you. That depends on your tumor, your health and your care team.
Sources
- FDA, FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer, 14 October 2026
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to BCG-unresponsive non-muscle invasive bladder cancer. The information below is general, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A news story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.